The Life Raft Group has been an integral part of a pan-cancer Working Group designed to determine consistent terminology around biomarker or mutational testing. The goal is to communicate to patients and the larger community in plain, patient friendly and consistent language what these terms mean, and how they impact on precision medicine.
COVID-19 - Resources GIST Patients Need - Please know that the Life Raft Group is here to support you during this Coronavirus crisis. We will continue our daily services during this time and we will be distributing information and messages of hope through all our communication channels.
Blueprint Medicines Announces Publication in The Lancet Oncology Showing Durable Clinical Benefits of AYVAKIT™ (avapritinib) in NAVIGATOR Trial Patients with PDGFRA D842V Mutant GIST.
For GIST Awareness Day, to celebrate our theme of #GISTHope, we’re asking you to spread the word about GIST on social media and out in the world.
The LRG was fortunate to get a few minutes with GIST specialist, Jonathan Trent, MD, Sylvester Comprehensive Cancer Center, who shared his experience with his patients over the past few months during the coronavirus pandemic.
Eric Lindberg, diagnosed with GIST in 2017, works as an emergency room nurse and has been on the frontlines throughout the COVID-19 pandemic.
Q&A with a LRG Major Donor & Fundraiser
For GIST patients, long term survival is the ultimate goal. A number of factors may influence long term survival – some of these are demographic and clinical, like mutational subtype and genetic factors. However, there are a number of others that are perhaps more subtle, such as lifestyle, attitude, and access to treatment, experts, and advice.
Amelia Yeo, LRG Country Liaison for Singapore and GIST caregiver, describes how she and her husband are doing during this global health pandemic.
Hope is an important resource during difficulty times. Mary Garland, Director of Communications for the LRG, shares her observations on hope.